<DOC>
	<DOCNO>NCT00002448</DOCNO>
	<brief_summary>The purpose study examine immune system HIV-infected patient react 2 anti-HIV drug combination .</brief_summary>
	<brief_title>A Study Compare Effects Two Anti-HIV Drug Combinations Immune Systems HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize two study arm least 48 week treatment . Arm A receives SQV SGC plus RTV plus two NRTIs choice . Arm B receive EFV plus two NRTIs choice . NRTIs approve study use stavudine ( d4T ) , didanosine ( ddI ) , zidovudine ( AZT ) , lamivudine ( 3TC ) , Combivir , zalcitabine ( ddC ) . Abacavir exclude . The following immunology variable HIV-1 viral characteristic evaluate study visit : CD4 CD8 cell count ; naive memory T-cells ; T-cell activation marker ( HLA-DR CD38 ) ; T-cells express T helper 1- ( TH1- ) T helper 2- ( TH2- ) associate intracytoplasmic cytokine ; anti-CD3 T-cell activation response ; T-cell receptor V Beta repertoire ; cytotoxic T-lymphocyte ( CTL ) activity level ; lymph node histology ( optional ) ; HIV-1 qualitative microcultures viral phenotyping non-syncytium-inducing ( NSI ) syncytium-inducing ( SI ) viral isolates . Laboratory determination , adverse effect , neurological exam ( include mental status evaluation ) , lipodystrophy parameter ( include fast lipid profile physical parameter ) also evaluate .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load least 5,000 copies/ml CD4 cell count great 75 cells/mm3 . Are least 16 ( need consent parent guardian 18 ) . Are able complete study . Exclusion Criteria Patients eligible study : Have ever take antiHIV medication . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>efavirenz</keyword>
</DOC>